亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Overcoming the challenges of tissue delivery for oligonucleotide therapeutics

内吞循环 寡核苷酸 内体 细胞生物学 核糖核酸 内化 生物 细胞 DNA 化学 基因 内吞作用 生物化学
作者
Tufan Gökirmak,Mehran Nikan,Svenja Wiechmann,Thazha P. Prakash,Michael Tanowitz,Punit P. Seth
出处
期刊:Trends in Pharmacological Sciences [Elsevier BV]
卷期号:42 (7): 588-604 被引量:61
标识
DOI:10.1016/j.tips.2021.04.010
摘要

Synthetic therapeutic oligonucleotides (STOs) target genes and gene products by utilizing endogenous endonucleases for the degradation of cellular RNA, RNA maturation pathways by modulating splicing, and protein translation by sterically blocking the access of ribosomal machinery to mRNA. STOs cross at least two phospholipid bilayers, plasma, and endosomal membranes, to reach their biological targets, mRNA and DNA inside cells. They enter the cell through receptor-mediated endocytic uptake and escape endosomal compartments to access the cytoplasm and/or nucleus, where they exert pharmacological effects through different antisense mechanisms. Backbone and sugar modifications improve the drug properties of STOs by increasing their metabolic stability and affinity for plasma proteins to reduce glomerular filtration and urinary excretion, thereby facilitating distribution to peripheral tissues. Subsequent interactions with cell surface proteins promotes cellular internalization by endocytic pathways. Next-generation oligonucleotide drugs are targeted therapeutics conjugated to endogenous or exogenous ligands for cell-surface receptors expressed in specific cell types or tissues. Givosiran (Givlaari®) is the first ligand conjugated STO developed by Alnylam for the treatment of adults with acute hepatic porphyria. Synthetic therapeutic oligonucleotides (STO) represent the third bonafide platform for drug discovery in the pharmaceutical industry after small molecule and protein therapeutics. So far, thirteen STOs have been approved by regulatory agencies and over one hundred of them are in different stages of clinical trials. STOs hybridize to their target RNA or DNA in cells via Watson-Crick base pairing to exert their pharmacological effects. This unique class of therapeutic agents has the potential to target genes and gene products that are considered undruggable by other therapeutic platforms. However, STOs must overcome several extracellular and intracellular obstacles to interact with their biological RNA targets inside cells. These obstacles include degradation by extracellular nucleases, scavenging by the reticuloendothelial system, filtration by the kidney, traversing the capillary endothelium to access the tissue interstitium, cell-surface receptor-mediated endocytic uptake, and escape from endolysosomal compartments to access the nuclear and/or cytoplasmic compartments where their targets reside. In this review, we present the recent advances in this field with a specific focus on antisense oligonucleotides (ASOs) and siRNA therapeutics. Synthetic therapeutic oligonucleotides (STO) represent the third bonafide platform for drug discovery in the pharmaceutical industry after small molecule and protein therapeutics. So far, thirteen STOs have been approved by regulatory agencies and over one hundred of them are in different stages of clinical trials. STOs hybridize to their target RNA or DNA in cells via Watson-Crick base pairing to exert their pharmacological effects. This unique class of therapeutic agents has the potential to target genes and gene products that are considered undruggable by other therapeutic platforms. However, STOs must overcome several extracellular and intracellular obstacles to interact with their biological RNA targets inside cells. These obstacles include degradation by extracellular nucleases, scavenging by the reticuloendothelial system, filtration by the kidney, traversing the capillary endothelium to access the tissue interstitium, cell-surface receptor-mediated endocytic uptake, and escape from endolysosomal compartments to access the nuclear and/or cytoplasmic compartments where their targets reside. In this review, we present the recent advances in this field with a specific focus on antisense oligonucleotides (ASOs) and siRNA therapeutics. chemically modified, short, single-stranded oligonucleotides (typically 12–20 mer) that bind to their target RNA by Watson-Crick base-pairing principles and modulate expression of their target mRNA by multiple antisense mechanisms. routes of drug administration where the compound is directly delivered into the tissue of interest. These methods of administration bypass tissue barriers such as the blood–brain barrier (BBB) and blood–retinal barrier and reduce exposure to systemic tissues. Examples of local delivery methods include intrathecal or intraocular injections for delivery to the CNS or the eye, and aerosol delivery to the lungs. an endonuclease that specifically cleaves the RNA strand of a DNA–RNA hybrid. ASOs bind to target mRNA through complementary base pairing, recruiting RNaseH1 that leads to degradation of the target mRNA, thus preventing the translation of mRNA into protein. an siRNA or miRNA-directed endonuclease that is composed of multiprotein complex, which incorporates one strand of a siRNA or miRNA duplex for interaction with complementary mRNA sequence. Upon activation, one of the proteins in the complex (Argonaute 2), cleaves the target mRNA. double-stranded short RNA or modified duplexes that mediate targeted mRNA degradation through RISC complex formation. routes of drug administration where the compound is directly delivered into the blood stream to access tissues. Systemic delivery methods for synthetic therapeutic oligonucleotides (STO) include intravenous, intramuscular, and subcutaneous injections.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
糖伯虎完成签到 ,获得积分10
41秒前
在水一方应助科研通管家采纳,获得10
45秒前
光合作用完成签到,获得积分10
1分钟前
1分钟前
精明晓刚发布了新的文献求助10
1分钟前
精明晓刚完成签到,获得积分10
2分钟前
2分钟前
搜集达人应助kangkang采纳,获得10
2分钟前
英姑应助科研通管家采纳,获得10
2分钟前
kangkang完成签到,获得积分20
3分钟前
3分钟前
刘紫媛发布了新的文献求助10
3分钟前
故意的冰淇淋完成签到 ,获得积分10
3分钟前
刘紫媛完成签到,获得积分20
3分钟前
Lucas应助Dave采纳,获得10
3分钟前
刘紫媛关注了科研通微信公众号
4分钟前
4分钟前
Akitten发布了新的文献求助10
4分钟前
草木完成签到 ,获得积分20
4分钟前
完美世界应助科研通管家采纳,获得10
4分钟前
领导范儿应助科研通管家采纳,获得10
4分钟前
Orange应助Boren采纳,获得10
5分钟前
5分钟前
Boren发布了新的文献求助10
5分钟前
大个应助Boren采纳,获得10
5分钟前
Raunio完成签到,获得积分10
5分钟前
Akitten发布了新的文献求助10
6分钟前
完美世界应助lhy采纳,获得10
6分钟前
科研通AI2S应助科研通管家采纳,获得10
6分钟前
7分钟前
7分钟前
7分钟前
Boren发布了新的文献求助10
7分钟前
lhy发布了新的文献求助10
7分钟前
董可以发布了新的文献求助10
7分钟前
风吹而过完成签到 ,获得积分10
7分钟前
乐乐应助董可以采纳,获得10
7分钟前
7分钟前
8分钟前
liufan完成签到 ,获得积分10
8分钟前
高分求助中
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3990332
求助须知:如何正确求助?哪些是违规求助? 3532146
关于积分的说明 11256483
捐赠科研通 3271042
什么是DOI,文献DOI怎么找? 1805207
邀请新用户注册赠送积分活动 882302
科研通“疑难数据库(出版商)”最低求助积分说明 809234